Zobrazeno 51 - 60
of 312
pro vyhledávání: ''
Autor:
Jacques Reynes, Stéphanie Badiou, Jean-Paul Cristol, Anne-Marie Dupuy, Vincent Baillat, Corinne Merle De Boever
Publikováno v:
Atherosclerosis. 172:273-279
Background: Low HDL-cholesterol, hypertriglyceridemia (HTG) and occurrence of small dense LDL could be involved in increased cardiovascular risk in HIV-infected patients. This study evaluates the effects of fenofibrate and/or Vitamin E on lipoprotein
Publikováno v:
Atherosclerosis. 171:369-377
Both atorvastatin and fenofibrate are known to lower postprandial chylomicrons and chylomicron remnants. However, until now it has not been investigated which of the two drugs is more effective in one and the same patient and, secondly, whether these
Autor:
Bengt Vessby, Lars Lind, Peter Steer, Hans Lithell, Christian Berne, Samar Basu, Jonas Millgård
Publikováno v:
Atherosclerosis. 168:65-72
An acute elevation of circulating non-esterified fatty acids (NEFAs) has previously been shown to impair endothelium-dependent vasodilation (EDV). In this study, we investigated if local administration of vitamin C (n=8, 18 mg/min), L-arginine (n=8,
Autor:
Benoît Lamarche, Mathieu Larivière, Claude Gagné, Jean Bergeron, Jean-Charles Hogue, Patrick Couture, Matteo Pirro
Publikováno v:
Atherosclerosis. 167:97-104
The effects of the HMG CoA reductase inhibitor atorvastatin on electrophoretic characteristics of LDL particles were evaluated in 46 patients (28 males and 18 females) with heterozygous familial hypercholesterolemia (FH) aged 20-61 carrying either a
Publikováno v:
Atherosclerosis. 164:179-185
Atherosclerosis is characterized by macrophage foam cells formation, which originate from differentiating blood monocytes that have taken up oxidized LDL (Ox-LDL) at enhanced rate. Statin therapy exhibit pleiotropic effects on many components of athe
Autor:
Reynald Dupuis, Pascal Egger, Arie van Tol, Maryse Guerin, Céline Soudant, M. John Chapman, Wilfried Le Goff
Publikováno v:
Atherosclerosis, 163, 287-296. Elsevier Ireland Ltd
Type IIB hyperlipidemia is associated with premature vascular disease, an atherogenic lipoprotein phenotype characterised by elevated levels of triglyceride-rich VLDL and small dense LDL, together with subnormal levels of HDL. The dose-dependent and
Autor:
Noriaki Nakaya, Hiroshi Mabuchi, Yoshiya Hata, Motoo Tushima, Nobuya Ogawa, Yuichiro Goto, Nobuhiro Yamada, Jun Sasaki, Hiroshige Itakura, Tamio Teramoto, Yasushi Saito
Publikováno v:
Atherosclerosis. 162:373-379
Pitavastatin (p-INN) is a novel and fully synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, with a cholesterol-lowering action stronger than that of other statins currently in use. A 12-week, multi-center, randomized, dou
Autor:
Joanne Bourgeois, Jean-Pierre Després, Vladimir Dzavik, Gérald Tremblay, L. Laperriere, Isabelle Lemieux
Publikováno v:
Atherosclerosis. 162:363-371
The objective of the present study was to compare the effects of a 16-week pharmacotherapy with fenofibrate (200 mg) or pravastatin (initially 20 mg for 8-weeks and, if necessary, increased to 40 mg) on low density lipoprotein (LDL) particle size ass
Publikováno v:
Atherosclerosis. 160:185-193
In a study comparing the effects of two continuous HRT regimens on cardiovascular risk markers, 43 postmenopausal women were randomly assigned to receive either tibolone 2.5 mg/day (n=20) or 0.625 mg/day conjugated equine oestrogens plus continuous m
Autor:
Adam B. Polis, Baishali M. Ambegaonkar, Joanne E. Tomassini, Diane Tipping, Andrew M. Tershakovec
Publikováno v:
Atherosclerosis. 237(2)
Objective : Evaluate the lipid-altering effects of ezetimibe added to ongoing statin therapy, statin titration, switching from statin monotherapy to a more potent statin or to ezetimibe/simvastatin. Methods : A pooled analysis of patient-level data f